



CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: CHRIS MYERS

Signature: Chris Myers

Date: March 16, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Information Disclosure Statement Address to: Commissioner of Patents PO Box 1450 Alexandria, VA 22313-1450	First Named Inventor	Robert Than Hendricks
	Application Number	10/731,581
	Filing Date	December 9, 2003
	Group Art Unit	to be assigned
	Examiner	
	Attorney Docket No.	R0148B-REG
	Title	Antiviral Nucleoside Derivatives

Sir:

Transmittal for Information Disclosure Statement

Transmitted herewith for filing in the above-entitled patent application is an Information Disclosure Statement, in compliance with 37 CFR §1.56, which may be material to the patentability of the subject patent application.

[X] Attached are:

- Form 1449, "Information Disclosure Statement By Applicants,"
- Copies of references B1 through B10 and C1 through C10.
- Return postcard

[X] The Information Disclosure Statement is being submitted (a) within three months of the filing date, or (b) before the mailing date of the first Office Action. **Therefore, no fee is due under 37 CFR 1.97(b).**

[X] Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,



Brian L. Buckwalter

Reg. No. 46,585

Agent for Applicants

Roche Palo Alto LLC
Patent Law Dept. M/S A2-250
3431 Hillview Avenue
Palo Alto, CA 94304
Direct Phone (650) 855-6995

Date: March 16, 2004



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTS**

Attorney Docket No.
R0148B-REG

Serial No.
10/731,581

Applicants
Robert Than Hendricks, et al.

Filing Date
December 9, 2003

Group
not known

U.S. PATENT DOCUMENTS

Exam Initial	Ref. #	Document #	Date	Name	Class/ Subclass	Filing Date
	A-1	3,998,807	21-Dec-1976	John G. Moffatt		
	A-2	4,957,924	18-Sep-1990	Lilia M. Beauchamp		
	A-3	5,216,142	01-Jun-1993	Horrobin, et al.		
	A-4	6,184,376	06-Feb-2001	Leanna, et al.		

FOREIGN PATENT DOCUMENTS

	Ref.#	Document #	Date	Country; Assignee	Translation	
					Yes	No
	B-1	WO 02/100415 A2	19-Dec-2002	F. Hoffmann-La Roche AG		
	B-2	WO 01/45509 A1	28-Jun-2001	ICN Pharmaceuticals		
	B-3	WO 01/68034 A2	20-Sep-2001	ICN Pharmaceuticals		
	B-4	WO 00/23454 A11	27-Apr-2000	Schering Corp.		
	B-5	WO 94/22887 A1	13-Oct-1994	Norsk Hydro A.S.		
	B-6	WO 94/24134 A1	27-Oct-1994	Hoechst AG		
	B-7	WO 93/07163 A1	15-Apr-1993	Norsk Hydro A.S.		
	B-8	EP 0 375 329 B1	27-Jun-1990	The Wellcome Foundation Ltd.		
	B-9	EP 0 343 133 b1	23-Nov-1989	Medivir Aktiebolag		
	B-10	WO 98/16186 A2	23-Apr-1998	ICN Pharmaceuticals		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANTS		Attorney Docket No. R0148B-REG	Serial No. 10/731,581
		Applicants Robert Than Hendricks, et al.	
		Filing Date December 9, 2003	Group not known
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	BALIMANE, et al., "Direct Evidence for Peptide Transporter (PEPT1)-Mediated Uptake of a Nonpeptide Prodrug, Valacyclovir," Biochemical and Biophysical Research Communications, (1998) pp. 246-251, vol. 250, Article No. RC989298	
	C2	BEAUCHAMP, et al., "Amino Acid Ester Prodrugs of Acyclovir," Antiviral Chemistry & Chemotherapy, (1992), pp. 157-164, 3(3)	
	C3	CHAMBERLAIN, et al., "2'-Ester Prodrugs of the Varicella-Zoster Antiviral Agent, 6-Methoxypurine Arabinoside," Antiviral Chemistry & Chemotherapy, (1992), pp. 371-378, 3(6)	
	C4	HARNDEN, et al., "Prodrugs of the Selective Antiherpesvirus Agent 9-[4-Hydroxy-3-(hydroxymethyl)but-1-yl]guanine (BRL 39123) with Improved Gastrointestinal Absorption Properties," J. Med. Chem., (1989), pp 1738-1743, 32	
	C5	HODGE, et al., "Selection of an Oral Prodrug (BRL 42810; Famciclovir) for the Antiherpesvirus Agent BRL 39123 [9-4(-Hydroxy-3-Hydroxymethylbut-1-yl)Guanine; Penciclovir]," Antimicrobial Agents and Chemotherapy, (1989), pp. 1765-1773, 33(10).	
	C6	JONES, et al. "Di- and Triester Prodrugs of the Varicella-Zoster Antiviral Agent 6-Methoxypurine Arabinoside," J. Med. Chem, (1992), pp. 56-63, 35.	
	C7	KIM, et al., "Synthesis and Evaluation of 2-Amino-9-(1,3-dihydroxy-2-propoxymethyl)-6-fluoropurine Mono- and Diesters as Potential Prodrugs of Ganciclovir," J. Med. Chem., (1999), pp. 324-328, 42.	
	C8	NIELSEN, et al., "Human Peptide Transporters: Therapeutic Applications," Expert Opinion, Ther. Patents (2002), pp. 1329-1350, 12(9), Ashley Publications	
	C9	PUE, et al., "Pharmacokinetics of Famciclovir in Man," Antiviral Chemistry & Chemotherapy, (1993), pp. 47-55, 4, Suppl. 1	
	C10	RUBIO-ALIAGA, et al., "Mammalian Peptide Transporters as Targets for Drug Delivery," Trends in Pharmacological Sciences, (2002), pp. 434-440, 23(9)	
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			